Guardant Health, Inc.

General information

Guardant Health, Inc.
3100 Hanover Street
94304 Palo Alto, California
USA

Contact person: Helmy Eltoukhy, Chairman and co-Chief Executive Officer
Company main phone: +1 (855) 6988887
Company main fax: +1 (888) 9744258
Website: https://www.guardanthealth.com

Year founded:	2012
Source of foundation:	Independent foundation
No. of employees:	Worldwide: 1999

Corporate description / mission:
Guardant Health is a precision oncology company focused on guarding wellness and giving every person more time free from cancer. Guardant is transforming patient care by providing critical insights into what drives disease through its advanced blood and tissue tests, real-world data and AI analytics. Guardant tests help improve outcomes across all stages of care, including screening to find cancer early, monitoring for recurrence in early-stage cancer, and helping doctors select the best treatment for patients with advanced cancer.

State of ownership: Publicly listed on stock exchange
Headquarters: HQ: Yes
IPO (year): 2018

Categorization

Sector:

Biotechnology - R&D Services

Subsector:

Other
Diagnostic instrumentation
Screening

Primary therapeutic areas:

Neoplasms / cancer / oncology

Business model:

Manufacturer
R&D
Service company
Supplier / Distributor

Customer segments:

Consumers (mass market)
Hospitals
Large medtech
Physicians / doctors

Distribution:

Direct (own sales force)

Summary Products / Services / Technologies

Description of products:
Guardant360® CDx
Guardant Reveal™ test
Guardant360 Response™
Guardant360 TissueNext, etc.

Financing details

Fiscal year (end of) 2024

Revenues:	USD 739.02M
R&D expenses:	USD 347.75M
Cash:	USD 525.54M

Total liabilities:	USD 1'625.26M
No. of shares:	123'421'000
Market cap. / valuation:	USD 5'258.97M

Collaborations & Clients

Partnering strategy / collaborations:
The company work with bio-pharmaceutical partners, digital health companies, patient advocacy groups and international distributors.